PDF, Patent Landscape Report on Atazanavir - WIPO

More documents

Recommendations

Info

C<strong>on</strong>tentsSECTION 1: THE TWO OBJECTIVES OF THE PROJECT ................................................. 4STUDYING DEVELOPMENT OF DRUGS THROUGH PATENTS ................................... 4BEST PRACTICES FOR COLLECTING AND ANALYZING PATENTS............................ 4ORGANIZATION OF THE REPORT................................................................................. 4SECTION 2: BUILDING A PATENT COLLECTION COVERING ATAZANAVIR .................. 6CHEMICAL NAMING ........................................................................................................ 7SUPPLEMENTAL PROTECTION CERTIFICATES .......................................................... 7CLINICAL NAMING..........................................................................................................10MANUFACTURER NAMING............................................................................................10GENERIC NAMING .........................................................................................................10BRAND NAMING .............................................................................................................10SECTION 3: PREPARING THE CLINICAL COLLECTION..................................................11STAGE ONE STRATEGY................................................................................................11STAGE TWO CLINICAL SEARCH ..................................................................................13CLINICAL COLLECTION .................................................................................................14CLINICAL COLLECTION .................................................................................................15SECTION 4: PREPARING THE CHEMICAL COLLECTION ...............................................16MULTI-FACETED APPROACH .......................................................................................16THE FOUNDER PATENT AND ITS DOWNSTREAM CITATIONS..................................17CHEMICAL COLLECTION...............................................................................................17CHEMICAL COLLECTION...............................................................................................18CHEMICAL COLLECTION...............................................................................................19SUMMARY OF COLLECTION ASSEMBLY.....................................................................20SECTION 5: GENERAL OVERVIEW OF THE COLLECTION ............................................21EARLIEST PRIORITY COUNTRY ...................................................................................21EARLIEST PRIORITY COUNTRY ...................................................................................22FAMILY MEMBER COUNTRIES .....................................................................................22FAMILY MEMBER COUNTRIES .....................................................................................23SECTION 6: EXAMINING ASPECTS OF DRUG DEVELOPMENT ....................................23SECTION 6: EXAMINING ASPECTS OF DRUG DEVELOPMENT ....................................24THE DEVELOPER’S OWN TIMELINE.............................................................................272
CATEGORIES WITH HIGHEST EMPHASIS ...................................................................30COMPARING TECHNICAL EMPHASIS OF TOP COMPANIES .....................................30ACTIVITY TIMELINES OF SELECTED COMPANIES.....................................................32PATENT QUALITY INDICATORS FOR SELECTED COMPANIES.................................32PATENT QUALITY INDICATORS FOR SELECTED COMPANIES.................................33SECTION 7: SPECIFIC ELEMENTS OF DEVELOPMENT .................................................34FOUNDER COMPOSITIONS ..........................................................................................34PROTEASE INHIBITOR BREAK-THROUGH ..................................................................36FORMULATIONS ............................................................................................................36FORMULATIONS ............................................................................................................37PROPRIETARY DRUGS AND LITIGATION ....................................................................41CLINICAL TRIALS AND PATENTING .............................................................................41SECTION 8: DRUG COMBINATIONS.................................................................................42COMBINATION TYPES ...................................................................................................42TWO DRUGS DIRECTED AT THE SAME TARGET .......................................................43TWO DRUGS DIRECTED AT DIFFERENT TARGETS ...................................................44USING OVERLAP TO FIND COMBINATIONS OF INTEREST .......................................47SECTION 9: USE OF CLASSIFICATION SYSTEMS TO ASSIST SEARCHING ................48INTERNATIONAL PATENT CLASSIFICATION AND RELATED SYSTEMS...................49US CLASSIFICATION SYSTEM......................................................................................51US CLASSIFICATION SYSTEM......................................................................................52DERWENT MANUAL CODES .........................................................................................53SECTION 10: RECAP .........................................................................................................543
Page 7 and 8: collection for nuggets of intellige
Page 9 and 10: CHEMICAL NAMINGChemical naming conv
Page 11 and 12: Figure 2: Legal Status for Novartis
Page 13 and 14: name, but after the patent protecti
Page 15 and 16: STAGE TWO CLINICAL SEARCHTo be more
Page 17 and 18: CLINICAL COLLECTIONThis is an examp
Page 19 and 20: THE FOUNDER PATENT AND ITS DOWNSTRE
Page 21 and 22: CHEMICAL COLLECTIONThis is an examp
Page 23 and 24: SECTION 5: GENERAL OVERVIEW OF THE
Page 25 and 26: FAMILY MEMBER COUNTRIESLooking at p
Page 27 and 28: The crossover between categories is
Page 29 and 30: THE DEVELOPER’S OWN TIMELINEThe A
Page 31 and 32: Several of the representative paten
Page 33 and 34: Figure 25. Emphasis Matrix for Sele
Page 35 and 36: PATENT QUALITY INDICATORS FOR SELEC
Page 37 and 38: Figure 30. References made by the F
Page 39 and 40: FORMULATIONSEven before a drug is a
Page 41 and 42: Figure 34. References to Bristol My
Page 43 and 44: PROPRIETARY DRUGS AND LITIGATIONThe
Page 45 and 46: TWO DRUGS DIRECTED AT THE SAME TARG
Page 47 and 48: Citations to this document mainly c
Page 49 and 50: USING OVERLAP TO FIND COMBINATIONS
Page 51 and 52: INTERNATIONAL PATENT CLASSIFICATION
Page 53 and 54:
ased on the IPC, but with sometimes
Page 55 and 56:
DERWENT MANUAL CODESDWPI Manual Cod
Page 58:
For more information contact WIPO a
show all

PDF, Patent Landscape Report on Atazanavir - WIPO

Create successful ePaper yourself

Delete template?

Save as template?